Guggenheim Reiterates Buy Rating on Johnson & Johnson
Guggenheim maintains its buy rating on Johnson & Johnson, setting a price target of $270, a 4.44% upside from the current price.
Key Points
- Guggenheim reiterated its buy rating on Johnson & Johnson, setting a price target of $270 on June 26, 2026.
- Guggenheim's $270 price target implies 4.44% upside from Johnson & Johnson's ($JNJ) current $258.51 share price.
- Johnson & Johnson shares traded at $244.88 on Friday, with a market cap of $589.5 billion and a P/E ratio of 28.41.
- Insiders at Johnson & Johnson have been active, with recent transactions including both purchases and sales.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Guggenheim reiterated its buy rating on Johnson & Johnson (NYSE:JNJ) on June 26, 2026, maintaining its price target at $270. Analyst Vamil Divan continues to express confidence in the company's prospects.
Johnson & Johnson Stock Down 2.8%
Shares of NYSE:JNJ traded near $244.88 on Friday. Johnson & Johnson boasts a market cap of about $589.5 billion and a P/E ratio of 28.41. The stock's 52-week range spans from $151.01 to $251.71, with a 50-day moving average of $230.34 and a 200-day moving average of $216.95. Its beta of 0.256 suggests lower volatility compared to the market.
$JNJ price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Johnson & Johnson reported revenues of approximately $96.36 billion, with a revenue growth of 9.9%. The company achieved a net margin of 21.83% and a return on equity of 26.42%. Its earnings per share stand at $8.62. The next earnings release is scheduled for July 15, 2026.
Dividend
Johnson & Johnson pays an annual dividend of $5.36 per share, yielding 2.19%. The dividend payout ratio is 60.25%, providing a steady income stream for investors.
Insider Buying and Selling at Johnson & Johnson
Insiders at Johnson & Johnson have been active recently. On June 11, 2026, Kathryn Wengel, EVP and Chief TO and Risk Officer, sold 10,000 shares at an average price of $241.15. On the same day, she also bought 10,000 shares at $115.67. Other insiders, including Marillyn Hewson, Eugene Woods, and Daniel Pinto, made smaller purchases on June 9, 2026, at $232.79 per share.
Analysts Set New Price Targets
On June 26, 2026, Guggenheim maintained its buy rating on Johnson & Johnson with a $270 price target. Previously, on May 13, 2026, Leerink Partners upgraded the stock to a buy with a $265 target. Barclays and Stifel both maintained their hold ratings in April 2026, with targets of $255 and $250, respectively. The consensus recommendation is a buy, with an average target price of $257.32 among 22 analysts.
About Johnson & Johnson
Johnson & Johnson, headquartered in New Brunswick, New Jersey, is a global healthcare company. It operates through two segments: Innovative Medicine and MedTech. The company develops and sells a wide range of healthcare products, including pharmaceuticals, medical devices, and consumer health products. Led by CEO Joaquin Duato, Johnson & Johnson employs over 138,200 people worldwide.
Bottom Line
Guggenheim's reiteration of a buy rating with a $270 target reflects continued optimism in Johnson & Johnson's performance. As a major player in the healthcare sector, the company remains under close watch by investors. This analyst update is part of the regular reviews that can influence investor sentiment, though it's important to remember that such ratings are based on past performance and projections.
Get Johnson & Johnson alerts
New 13F filings, insider trades, and analyst moves on $JNJ, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.